Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations
Conference Call Scheduled for Monday, April 16, at 8:30 AM EDT
DANBURY, Conn., April 15, 2012 /PRNewswire via COMTEX/ -- Biodel Inc. BIOD -1.82% today announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BIOD-125 -- two proprietary ultra-rapid-acting formulations of recombinant human insulin (RHI).
BIOD-123 and BIOD-125 achieved the Company's target pharmacokinetic, pharmacodynamic and toleration profiles in a Phase 1 clinical trial; BIOD-123 favored as lead product candidate to advance to Phase 2
Projecting initiation of a Phase 2 clinical trial of BIOD-123 in the third calendar quarter of 2012